DG
BCLI

Delek Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Delek Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$139K Sell
2,394
-429
-15% -$25K 0.01% 214
2019
Q1 		$183K Buy
+2,823
New +$161K 0.01% 200

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wolverine Trading
Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Delek Group's BCLI Position: Q2 2019 in Review

Delek Group reduced its BRAINSTORM CELL THERAPUTC (BCLI) stake by 15% in Q2 2019, selling an estimated $25K and leaving 2,394 shares worth $139K. The position accounts for 0.01% of the portfolio, ranked #214.

Delek Group first reported a position in BCLI in Q1 2019 and has held it in 2 quarters since. The position peaked at $183K in Q1 2019. 37 funds tracked by Wall St. Rank hold BCLI as of Q2 2019.

  • Delek Group held 2,394 shares of BRAINSTORM CELL THERAPUTC worth $139K as of Q2 2019.
  • Delek Group sold 429 BRAINSTORM CELL THERAPUTC shares in Q2 2019, an estimated $25K.
  • BRAINSTORM CELL THERAPUTC made up 0.01% of Delek Group's portfolio in Q2 2019, its #214 holding.
  • Delek Group first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2019 and has held it in 2 quarters since.
  • Delek Group's BRAINSTORM CELL THERAPUTC position peaked at $183K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.